Skip to Main Content

Amarin (AMRN) markets a prescription fish-oil pill, Vascepa, to treat patients with excessive levels of a type of fat found in the blood. Vascepa sales have been modest, however, because Amarin lacks scientific proof that reducing this fat in blood prevents heart attacks, stroke, or cardiovascular deaths.

But after years of effort, Amarin is finally nearing completion of a massive cardiovascular outcomes trial called REDUCE-IT, which will help settle this important scientific and commercial question about Vascepa’s ultimate benefit to patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.